^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Elrexfio (elranatamab-bcmm)

    i
    Other names: PF-06863135, PF 06863135, PF06863135, PF‑3135, PF3135, RN 613, RN613, RN-613
    Company:
    Pfizer
    Drug class:
    CD3 agonist, BCMA inhibitor
    Related drugs:
    23d
    Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance (clinicaltrials.gov)
    P2, N=65, Not yet recruiting, Washington University School of Medicine | Trial completion date: Sep 2031 --> Dec 2031 | Initiation date: Sep 2024 --> Dec 2024 | Trial primary completion date: Sep 2031 --> Dec 2031
    Trial completion date • Trial initiation date • Trial primary completion date • Post-transplantation
    |
    clonoSEQ
    |
    Elrexfio (elranatamab-bcmm)
    27d
    EMBRACE: Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
    P2, N=40, Not yet recruiting, Ontario Clinical Oncology Group (OCOG) | Initiation date: Jul 2024 --> Nov 2024
    Trial initiation date • IO biomarker
    |
    Elrexfio (elranatamab-bcmm)
    1m
    MagnetisMM-5: Study of Elranatamab (PF-06863135) Monotherapy and Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
    P3, N=761, Recruiting, Pfizer | Active, not recruiting --> Recruiting
    Enrollment open
    |
    lenalidomide • dexamethasone • pomalidomide • Elrexfio (elranatamab-bcmm) • Darzalex Faspro (daratumumab and hyaluronidase-fihj)
    1m
    A Study to Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory Multiple Myeloma as Compared With Standard of Care Therapies (clinicaltrials.gov)
    P=N/A, N=1, Active, not recruiting, Pfizer | N=700 --> 1
    Enrollment change
    |
    Elrexfio (elranatamab-bcmm)
    2ms
    Non Interventional Study to Investigate the Safety and Effectiveness in Patients With Relapsed and Refractory Multiple Myeloma Treated With Elranatamab Under the Actual Use. (clinicaltrials.gov)
    P=N/A, N=1, Active, not recruiting, Pfizer | Not yet recruiting --> Active, not recruiting | N=430 --> 1
    Enrollment closed • Enrollment change
    |
    Elrexfio (elranatamab-bcmm)
    2ms
    MAGNETISMM-2: Study of Elranatamab (PF-06863135) in Japanese Participants With Multiple Myeloma (clinicaltrials.gov)
    P1, N=4, Completed, Pfizer | Active, not recruiting --> Completed
    Trial completion • Metastases
    |
    Elrexfio (elranatamab-bcmm)
    2ms
    A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma. (clinicaltrials.gov)
    P1/2, N=38, Active, not recruiting, Pfizer | Phase classification: P2 --> P1/2
    Phase classification • Immunomodulating
    |
    Elrexfio (elranatamab-bcmm)
    2ms
    MagnetisMM-5: Study of Elranatamab (PF-06863135) Monotherapy and Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
    P3, N=761, Active, not recruiting, Pfizer | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    lenalidomide • pomalidomide • Elrexfio (elranatamab-bcmm) • Darzalex Faspro (daratumumab and hyaluronidase-fihj)
    2ms
    A Study to Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory Multiple Myeloma as Compared With Standard of Care Therapies (clinicaltrials.gov)
    P=N/A, N=700, Active, not recruiting, Pfizer
    New trial • HEOR • Real-world evidence • Real-world
    |
    Elrexfio (elranatamab-bcmm)
    2ms
    Korean Post Marketing Surveillance for ELREXFIO (Elranatamab). (clinicaltrials.gov)
    P=N/A, N=150, Not yet recruiting, Pfizer
    New trial
    |
    Elrexfio (elranatamab-bcmm)
    3ms
    Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis (clinicaltrials.gov)
    P1/2, N=49, Not yet recruiting, Brigham and Women's Hospital
    New P1/2 trial
    |
    Elrexfio (elranatamab-bcmm)
    3ms
    MagnetisMM-20: A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=90, Recruiting, Pfizer | Trial completion date: Mar 2028 --> Nov 2027 | Trial primary completion date: May 2026 --> Dec 2025
    Trial completion date • Trial primary completion date • Combination therapy
    |
    carfilzomib • Elrexfio (elranatamab-bcmm) • maplirpacept (TTI-622)
    4ms
    Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma (clinicaltrials.gov)
    P2, N=40, Recruiting, M.D. Anderson Cancer Center | Not yet recruiting --> Recruiting
    Enrollment open • Pre-transplantation • Post-transplantation
    |
    lenalidomide • Elrexfio (elranatamab-bcmm) • busulfan • captisol-enabled melphalan • plerixafor
    4ms
    A Study to Compare the Effects of Elranatamab (PF 06863135) Versus Standard of Care (SOC) in Patients With Multiple Myeloma (MM) in Germany and US (clinicaltrials.gov)
    P=N/A, N=2, Completed, Pfizer
    New trial
    |
    Elrexfio (elranatamab-bcmm)
    4ms
    Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance Using Peripheral Blood Clonotypic Mass Spectrometry (clinicaltrials.gov)
    P2, N=65, Not yet recruiting, Washington University School of Medicine
    New P2 trial • Post-transplantation
    |
    Elrexfio (elranatamab-bcmm)
    5ms
    Non Interventional Study to Investigate the Safety and Effectiveness in Patients With Relapsed and Refractory Multiple Myeloma Treated With Elranatamab Under the Actual Use. (clinicaltrials.gov)
    P=N/A, N=430, Not yet recruiting, Pfizer
    New trial
    |
    Elrexfio (elranatamab-bcmm)
    5ms
    A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30) (clinicaltrials.gov)
    P1, N=100, Recruiting, Pfizer | Trial completion date: Mar 2028 --> Jul 2028 | Trial primary completion date: Apr 2027 --> Aug 2027
    Trial completion date • Trial primary completion date • Combination therapy
    |
    Elrexfio (elranatamab-bcmm) • iberdomide (CC-220)
    5ms
    MagnetisMM-20: A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=90, Recruiting, Pfizer | Trial primary completion date: Feb 2026 --> May 2026
    Trial primary completion date • Combination therapy
    |
    carfilzomib • Elrexfio (elranatamab-bcmm) • maplirpacept (TTI-622)
    5ms
    MagnetisMM-5: Study of Elranatamab (PF-06863135) Monotherapy and Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
    P3, N=761, Recruiting, Pfizer | Trial completion date: Sep 2026 --> May 2027 | Trial primary completion date: Dec 2024 --> Aug 2025
    Trial completion date • Trial primary completion date
    |
    lenalidomide • pomalidomide • Elrexfio (elranatamab-bcmm) • Darzalex Faspro (daratumumab and hyaluronidase-fihj)
    6ms
    EMBRACE: Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
    P2, N=40, Not yet recruiting, Ontario Clinical Oncology Group (OCOG)
    New P2 trial • IO biomarker
    |
    Elrexfio (elranatamab-bcmm)
    6ms
    ERASMM: Use of Elranatamab in Patients With High-risk Smoldering Multiple Myeloma (clinicaltrials.gov)
    P2, N=50, Recruiting, Stichting European Myeloma Network | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Elrexfio (elranatamab-bcmm)
    6ms
    ERASMM: Use of Elranatamab in Patients With High-risk Smoldering Multiple Myeloma (clinicaltrials.gov)
    P2, N=50, Not yet recruiting, Stichting European Myeloma Network | Initiation date: Jan 2024 --> May 2024
    Trial initiation date
    |
    Elrexfio (elranatamab-bcmm)
    7ms
    MagnetisMM-20: A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=90, Recruiting, Pfizer | Trial primary completion date: Aug 2025 --> Feb 2026
    Trial primary completion date • Combination therapy
    |
    carfilzomib • Elrexfio (elranatamab-bcmm) • maplirpacept (TTI-622)
    7ms
    Elranatamab in R/R Multiple Myeloma (clinicaltrials.gov)
    P2, N=32, Recruiting, Massachusetts General Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Elrexfio (elranatamab-bcmm) • Abecma (idecabtagene vicleucel)
    7ms
    MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma (clinicaltrials.gov)
    P2, N=120, Recruiting, Pfizer | N=92 --> 120
    Enrollment change • Combination therapy
    |
    lenalidomide • dexamethasone • Elrexfio (elranatamab-bcmm) • Ogsiveo (nirogacestat)
    8ms
    MagnetisMM-20: A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=90, Recruiting, Pfizer | N=14 --> 90
    Enrollment change • Combination therapy
    |
    carfilzomib • Elrexfio (elranatamab-bcmm) • maplirpacept (TTI-622)
    8ms
    Study of Elranatamab for Relapsed or Refractory Myeloma in Patients Previously Exposed to Three-drug Classes (clinicaltrials.gov)
    P2, N=50, Recruiting, PETHEMA Foundation | Not yet recruiting --> Recruiting | Initiation date: Mar 2024 --> Nov 2023
    Enrollment open • Trial initiation date
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase) • CD19 (CD19 Molecule) • CD38 (CD38 Molecule) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • NCAM1 (Neural cell adhesion molecule 1) • CD27 (CD27 Molecule) • CD81 (CD81 Molecule)
    |
    CD38 expression • CD19 expression • NCAM1 expression • CD27 expression • CD5 overexpression • NCAM1 overexpression
    |
    Elrexfio (elranatamab-bcmm)
    8ms
    MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb (clinicaltrials.gov)
    P2, N=187, Active, not recruiting, Pfizer | Trial completion date: Apr 2024 --> Dec 2025
    Trial completion date • Immunomodulating
    |
    Elrexfio (elranatamab-bcmm)
    9ms
    A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30) (clinicaltrials.gov)
    P1, N=100, Recruiting, Pfizer | Not yet recruiting --> Recruiting | Trial completion date: Jun 2028 --> Mar 2028 | Trial primary completion date: Aug 2026 --> Apr 2027
    Enrollment open • Trial completion date • Trial primary completion date • Combination therapy
    |
    Elrexfio (elranatamab-bcmm) • iberdomide (CC-220)
    9ms
    Phase II Study of Elranatamab as Single Agent for Relapsed or Refractory Myeloma in Patients Previously Exposed to Three-drug Classes (clinicaltrials.gov)
    P2, N=50, Not yet recruiting, PETHEMA Foundation
    New P2 trial
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase) • CD19 (CD19 Molecule) • CD38 (CD38 Molecule) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • NCAM1 (Neural cell adhesion molecule 1) • CD27 (CD27 Molecule) • CD81 (CD81 Molecule)
    |
    CD38 expression • CD19 expression • NCAM1 expression • CD27 expression • CD5 overexpression • NCAM1 overexpression
    |
    Elrexfio (elranatamab-bcmm)
    9ms
    MagnetisMM-1: PF-06863135 As Single Agent And In Combination With Immunomodulatory Agents In Relapse/Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=101, Completed, Pfizer | Active, not recruiting --> Completed
    Trial completion • Combination therapy • Immunomodulating • Metastases
    |
    lenalidomide • pomalidomide • Elrexfio (elranatamab-bcmm)
    9ms
    ERICA: Self-administration of Subcutaneous Elranatamab in the Patients' Homes. (clinicaltrials.gov)
    P2, N=20, Not yet recruiting, Odense University Hospital | Initiation date: Jan 2024 --> May 2024
    Trial initiation date
    |
    Elrexfio (elranatamab-bcmm)
    9ms
    MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide) (clinicaltrials.gov)
    P3, N=492, Recruiting, Pfizer | Not yet recruiting --> Recruiting
    Enrollment open
    |
    lenalidomide • bortezomib • carfilzomib • pomalidomide • Elrexfio (elranatamab-bcmm) • Empliciti (elotuzumab)
    10ms
    A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30) (clinicaltrials.gov)
    P1, N=100, Not yet recruiting, Pfizer
    New P1 trial • Combination therapy
    |
    Elrexfio (elranatamab-bcmm) • iberdomide (CC-220)
    10ms
    Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma (clinicaltrials.gov)
    P2, N=40, Not yet recruiting, M.D. Anderson Cancer Center
    New P2 trial • Pre-transplantation • Post-transplantation
    |
    lenalidomide • Elrexfio (elranatamab-bcmm) • busulfan • captisol-enabled melphalan • plerixafor
    10ms
    MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma (clinicaltrials.gov)
    P2, N=92, Recruiting, Pfizer | Phase classification: P1b/2 --> P2 | Trial completion date: Sep 2027 --> Jun 2027 | Trial primary completion date: Mar 2025 --> Jul 2025
    Phase classification • Trial completion date • Trial primary completion date • Combination therapy
    |
    lenalidomide • dexamethasone • Elrexfio (elranatamab-bcmm) • Ogsiveo (nirogacestat)
    11ms
    ERASMM: A Phase 2 Study of Elranatamab in Patients With High-risk Smoldering Multiple Myeloma (clinicaltrials.gov)
    P2, N=50, Not yet recruiting, European Myeloma Network
    New P2 trial
    |
    Elrexfio (elranatamab-bcmm)
    11ms
    A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma. (clinicaltrials.gov)
    P2, N=39, Active, not recruiting, Pfizer | Phase classification: P1b/2 --> P2
    Phase classification • Immunomodulating
    |
    Elrexfio (elranatamab-bcmm)
    11ms
    A Study to Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory Multiple Myeloma (clinicaltrials.gov)
    P=N/A, N=1, Completed, Pfizer | N=646 --> 1
    Enrollment change • HEOR • Real-world evidence • Real-world
    |
    Elrexfio (elranatamab-bcmm)
    12ms
    An Indirect Comparison of Elranatamab's Progression-Free Survival and Overall Survival from Magnetismm-3 Versus Real-World External Control Arms in Triple-Class Refractory Multiple Myeloma (ASH 2023)
    Treatment regimens in the RWD sources included various combinations of PIs (carfilzomib- and bortezomib-based regimens were each used by 43% and 15% of patients, respectively), IMiDs (lenalidomide- and pomalidomide-based regimens were used by 9% and 41% of patients, respectively), and mAbs (daratumumab- and isatuximab-based regimens were used by 32% and 1% of patients, respectively), among other agents (eg, selinexor-based regimens were used by 5% of patients). 66, respectively). CONCLUSIONSAmong BCMA-naïve patients who resemble those enrolled in the MM-3 trial, those treated with ELRA exhibit significantly longer PFS and OS compared with real-world treatments.
    Clinical • Real-world evidence • Real-world
    |
    lenalidomide • bortezomib • Xpovio (selinexor) • Darzalex (daratumumab) • carfilzomib • pomalidomide • Sarclisa (isatuximab-irfc) • Elrexfio (elranatamab-bcmm)
    12ms
    Safety of Elranatamab in Patients with Triple-Class Refractory Relapsed/Refractory Multiple Myeloma (RRMM) in Magnetismm-17, a North American Expanded Access Protocol (ASH 2023)
    The most common (occurring in ≥3 &lsqb;15%] patients) cytopenias were neutropenia (30%; G3/4 25%), lymphopenia (20%; G3/4 15%), and thrombocytopenia (15%; G3/4 10%). CONCLUSIONSEarly safety data (median treatment duration <1 month) from this ongoing expanded access protocol of elranatamab in patients with RRMM are consistent with results from the phase 2, registrational MagnetisMM-3 trial, with no new safety signal identified.
    Clinical
    |
    Elrexfio (elranatamab-bcmm)
    12ms
    A Matching-Adjusted Indirect Comparison of the Efficacy of Elranatamab Versus Physician's Choice of Treatment in Patients with Triple-Class Exposed/Refractory Multiple Myeloma (ASH 2023)
    CONCLUSIONSIn this MAIC, elranatamab demonstrated significantly higher ORR, higher ≥CR rate, longer PFS, and longer OS compared with PCT in the real-world. These results suggest that elranatamab offers significantly improved outcomes versus standard treatments used in patients with TCE/R MM in clinical practice.
    Clinical
    |
    Elrexfio (elranatamab-bcmm)